Showing 1 to 1 of 1 results
elmundo.es
🌐 85% Global Worthiness


DLBCL Treatment: High Relapse Rates, Promising Immunotherapies
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma, affects around 3,000 people annually in Spain; while 60-70% of patients are cured with initial chemotherapy, 40% relapse, necessitating innovative treatments like CAR-T cell therapy, which offers a 40% cure rate but...
DLBCL Treatment: High Relapse Rates, Promising Immunotherapies
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma, affects around 3,000 people annually in Spain; while 60-70% of patients are cured with initial chemotherapy, 40% relapse, necessitating innovative treatments like CAR-T cell therapy, which offers a 40% cure rate but...
Progress
52% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results